Jump to content

Paroxetine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 64: Line 64:
==Paroxetine controlled release (CR)==
==Paroxetine controlled release (CR)==


Paroxetine controlled release contains a Geomatrix™ tablet that controls the absorption of the drug. Clinical studies show that controlled release tablet provides effective symptom relief with a lower number of patients stopping their treatment due to side effects.<ref>{{cite journal | author=Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. | title=Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. | journal=Journal of Clinical Psychiatry | volume=63 | issue=7 | year=2002 | pages=577-584| id=PMID 12143913 }}</ref>
Paroxetine controlled release contains a [[Geomatrix]]™ tablet that controls the absorption of the drug. Clinical studies show that controlled release tablet provides effective symptom relief with a lower number of patients stopping their treatment due to side effects.<ref>{{cite journal | author=Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. | title=Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. | journal=Journal of Clinical Psychiatry | volume=63 | issue=7 | year=2002 | pages=577-584| id=PMID 12143913 }}</ref>


However, the need for an extended release form of paroxetine has not been established, as the FDA indicated that the half-life for the original Paxil was ideal for once-daily dosing, and that a CR version was not needed.
However, the need for an extended release form of paroxetine has not been established, as the FDA indicated that the half-life for the original Paxil was ideal for once-daily dosing, and that a CR version was not needed.

Revision as of 22:45, 14 February 2007

Paroxetine
Clinical data
License data
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: WARNING[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilitycomplete absorption from GI, but extensive first-pass-metabolization in the liver; max concentration 4.9 (with meals) to 6.4 hours (fasting)
Metabolismextensive, probable hepatic
Elimination half-life24 hours (range 3-65 hours)
Excretion66% urine, 37% bile
Identifiers
  • (3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-
    4-(4-fluorophenyl)-piperidine
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.112.096 Edit this at Wikidata
Chemical and physical data
FormulaC19H20FNO3
Molar mass374.8 g·mol−1

Paroxetine or paroxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It was released in 1992 by the pharmaceutical company GlaxoSmithKline and has since become one of the most prescribed antidepressants on the market due to its apparent efficacy in treating depression as well as a spectrum of anxiety disorders ranging from panic attacks to phobias. The prescription of this drug is currently controversial because of legal proceedings against the manufacturer (see controversy below).

Trade names

Paroxetine is marketed under several tradenames:

Indications

Approved

Paroxetine is primarily used to treat the symptoms of depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder (GAD), [2] social phobia/social anxiety disorder, [3] and premenstrual dysphoric disorder (PMDD).[4]

It was the first (and as of 2002, the only) antidepressant formally approved in the United States for the treatment of social anxiety disorder, causing it to be sometimes referred to (although inaccurately) as an anti-shyness drug.

Clinical Trials

Trials for Paxil CR have not lasted more than twelve months. The effectiveness of Paxil in major depressive disorders has been proven by two twelve week clinical trials in which the patients either had flexible doses or a placebo. Both of the studies concluded that Paxil is significantly more effective than the placebo control group. For another disorder, three 10-week studies were conducted to prove the effectiveness of Paxil CR on panic disorders. In the first and second studies, Paxil proved consistently better than the placebo. But the third trial Paxil CR failed to have any significant difference to the placebo. For social anxiety disorder, a 12-week trial for adult outpatients was conducted to show Paxil's effectiveness against the disease and prior information of Paxil's nature in the immediate release formulation. The study did not include adolescents with the disorder. The study also showed an increased risk of suicide in all age groups.

Unapproved/Off-label/Investigational

Paroxetine can also be used in the treatment of premature ejaculation,[5] chronic headache,[6] and bipolar disorder.[7]

Paroxetine has not been found to significantly reduce the symptoms of diabetic neuropathy.[8]

There is also evidence that paroxetine may be effective in the treatment of compulsive gambling[9] and hot flashes.[10]

Pharmacology

Paroxetine is the most potent selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor (SSRI).[citation needed] This activity of the drug on brain neurons is thought to be responsible for its antidepressant effects.

Paroxetine is a phenylpiperidine derivative which is chemically unrelated to the tricyclic or tetracyclic antidepressants. In receptor binding studies, paroxetine did not exhibit significant affinity for the adrenergic (α1, α2, β), dopaminergic, serotonergic (5HT1, 5HT2), or histamine receptors of rat brain membrane. A weak affinity for the muscarinic acetylcholine and noradrenaline receptors was evident. The predominant metabolites of paroxetine are essentially inactive as 5-HT reuptake inhibitors.

Paroxetine controlled release (CR)

Paroxetine controlled release contains a Geomatrix™ tablet that controls the absorption of the drug. Clinical studies show that controlled release tablet provides effective symptom relief with a lower number of patients stopping their treatment due to side effects.[11]

However, the need for an extended release form of paroxetine has not been established, as the FDA indicated that the half-life for the original Paxil was ideal for once-daily dosing, and that a CR version was not needed.

Chemistry

Paroxetine hydrochloride is an odorless, off-white powder, having a melting point range of 120° to 138°C and a solubility of 5.4 mg/mL in water.

Formulations

Paxil / Seroxat (paroxetine) is available in 10, 20, 30, and 40 mg tablets.

Paxil CR (paroxetine extended release) is available in 12.5, 25, and 37.5 mg tablets.

Paxil, Seroxat and Paxil CR are manufactured by GlaxoSmithKline, however a generic is now available under the chemical name paroxetine.

Side effects

General side effects are mostly present during the first 1-4 weeks while the body adapts to the drug. Almost all SSRIs are known to cause either one or more of these symptoms. A person receiving paroxetine treatment may experience a few, all, or none of the following side-effects, and most side-effects will disappear or lessen with continued treatment, though some may last throughout the duration.

Individuals experiencing any of the following symptoms should contact their doctor immediately:

  • Jaw, neck, and back muscle spasms
  • Fever, chills, sore throat, or flu-like symptoms
  • Yellowing of the skin or eyes
  • Black, tarry stools (this can indicate upper GI bleeding)

Paroxetine and other SSRIs have been shown to cause sexual side effects in most patients, both males and females[13]. Although usually reversible, these sexual side effects can sometimes last for months, years or possibly indefinitely even after the drug has been completely withdrawn. This disorder is known as Post SSRI Sexual Dysfunction.

Discontinuation syndrome

Main article: SSRI discontinuation syndrome

While any psychoactive medication (from caffeine to anti-psychotics) can cause withdrawal symptoms upon discontinuation from acute administration, anecdotal evidence suggests that paroxetine has a higher incidence rate and severity of SSRI discontinuation syndrome than other SSRIs and psychoactive medications, vertigo and hot flashes being prevalent.[14] For those experiencing extreme and unusual difficulty discontinuing paroxetine, it is recommended that an SSRI with a longer half-life, such as fluoxetine, be administered for approximately two weeks, then discontinued, to lessen symptoms.[15][16]

Suicidal ideation is a frequently reported experience in those withdrawing from SSRIs.[17] Withdrawal from paroxetine or any other SSRI should be medically supervised.

Warning for Pregnant Women

Pregnant women and those who might become pregnant should avoid taking the antidepressant Paxil because of a high risk of birth defects, according to a committee of obstetricians who published their opinion in the December issue of the journal Obstetrics & Gynecology.[18]

The obstetric practice committee of the American College of Obstetricians and Gynecologists said pregnant women should not take Paxil because two previous studies found that the drug posed up to double the risk of heart defects in fetuses.

Nearly a year ago, the U.S. Food and Drug Administration (FDA) and GlaxoSmithKline -- which makes Paxil -- changed the warnings on the drug to include the results of the studies. The FDA then advised pregnant women to merely switch from Paxil to another SSRI drug, such as Prozac or Zoloft.

The FDA's enhanced warning on Paxil followed the results of a review of Sweden's birth registry that found pregnant women who took Paxil were 1.5 to 2 times more likely to give birth to a baby with heart defects than women who took other SSRIs or who did not take antidepressants at all.

Neonatal withdrawal symptoms from Paxil have also been documented from mothers taking Paxil during pregnancy.[19]

Controversy

On October 6, 2006, a US court preliminarily approved a settlement in a class action lawsuit brought on behalf of everyone in the United States who purchased Paxil(R) or Paxil CR(TM) prescribed for consumption by a minor child. The lawsuit alleges that GlaxoSmithKline promoted Paxil(R) or Paxil CR(TM) for prescription to children and adolescents while withholding and concealing material information about the medication's safety and effectiveness for minors. GSK denies all claims. If approved, the Proposed Settlement will provide $63.8 million to pay consumers, who submit valid Claim Forms, cash for the total amount they paid for Paxil(R) or Paxil CR(TM). Eligible Class Members can get up to 100% of the amount paid for Paxil(R) or Paxil CR(TM).[citation needed]

The Court will hold a Final Approval Hearing on March 9,2007. At that time, the Court will consider whether to approve the Proposed Settlement and award attorneys' fees and costs. [20]

In March 2004 the FDA placed a black box warning on SSRI and other antidepressants, warning of the risk for potential suicidal thinking in children and adolescents. ABC News reported that the prescribing of these medications to children subsequently dropped by 20 percent. According to the Center for Disease Control and Prevention's Annual Summary of Vital Statistics, the suicide rate rose more than 18 percent in those 1 to 19 years old, from 2.2 per 100,000 in 2003 to 2.6 per 100,000 in 2004. In those 15 to 19 years old, the figures reflected a more than 12 percent rise in suicide, from 7.3 per 100,000 in 2003 to 8.2 per 100,000 in 2004. This led many experts to conclude that the warning, and subsequent reduction in the use of antidepressants, led to an increased suicide rate in this age group. The finding is consistent with an earlier finding, reported to the 2003 FDA Advisory Committee by Dr David Shaffer, that suicide rates in the United States fell during the 1990s, in line with the introduction of SSRIs.

Inevitably these particular statistics (and the conclusions drawn from them) are already being considered controversial by commentators in the UK,[21] and the USA.[22]

The claimed causal linkage is negated by the facts. In October 2004, the American Psychiatric Association wrote: "In 2003, U.S. physicians wrote 15 million antidepressant prescriptions for patients under age 18, according to FDA data. In the first six months of 2004, antidepressant prescriptions for children increased by almost 8 percent, despite the new drug labeling."[23]

According to these facts, antidepressant prescriptions for children increased by almost 8% in the first six months of 2004, if this is the case, it is difficult to link an increased suicide rate the same year to reduced use of antidepressants.

So despite the suggestions of a connection between the drop in SSRI prescriptions (even this fact is a matter of debate) and the spike in child and teen suicides, much more research will be needed before a conclusive link can be drawn.

Since the FDA approved paroxetine in 1992, approximately 5,000 U.S. citizens have sued GSK. Most of these people feel they were not sufficiently warned in advance of the drug's side effects.

According to the Paxil Protest website,[24] hundreds more lawsuits have been filed against GSK.[25] The Paxil Protest website was launched August 8, 2005 to offer both information about the protest and information on Paxil previously unavailable to the public. Just three weeks after its launch, the site received more than a quarter of a million hits. The site quickly fell out of use and is no longer functioning. It is understood that the action to remove the site from the internet was undertaken taken as part of a confidentiality agreement or 'gagging order' which the owner of the site entered into as part of a settlement of his action against GlaxoSmithKline. Gagging orders are common in such cases and can extend to documents that defendants wish to remain hidden from the public. However in some cases, such documents can become public at a later date, such as those made public by Dr. Peter Breggin in February of 2006.[26]

In January 2007, according to the Seroxat Secrets website,[27] the national group litigation in the United Kingdom, on behalf of several hundred people who allege withdrawal reactions through their use of the drug Seroxat, against GlaxoSmithKline plc, moved a step closer to the High Court in London, with the confirmation that Public Funding had been reinstated following a decision by the Public Interest Appeal Panel. The issue at the heart of this particular action claims Seroxat is a defective drug in that it has a propensity to cause a withdrawal reaction. Hugh James Solicitors have confirmed this news.[28]

On January 29 2007, the BBC in the UK broadcast a fourth documentary in its 'Panorama' series about the drug Seroxat.[29] This programme, entitled Secrets of the Drug Trials, focuses on on three GSK paediatric clinical trials on depressed children and adolescents. Data from the trials show that Seroxat could not be proven to work for teenagers. Not only that, one clinical trial indicated that they were six times more likely to become suicidal after taking it. In the programme, Panorama revealed the secret trail of internal emails which show how GlaxoSmithKline manipulated the results of the trials for its own commercial gain. Access to the documents has been gained as GlaxoSmithKline fights a fraud trial in the US. In common with previous editions, the programme presented an entirely one-sided picture of events, and could be argued was little more than a television broadcast on behalf of Baum Hedlund, the lawyers acting against GSK.

What cannot be denied is that the release into the public domain of previously secret Glaxo documents,[30] can only serve to stimulate discussion and debate regarding the way certain companies choose to market their products.

Footnotes

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 19 (6): 567–596. PMID 16272179.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ D Baldwin, J Bobes, DJ Stein, I Scharwachter and M Faure (1999). "Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group". The British Journal of Psychiatry. 175: 120–126. PMID 10627793.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. (1996). "Paroxetine as a treatment for premenstrual dysphoric disorder". Journal of Clinical Psychopharmacology. 16 (1): 3–8. PMID 8834412.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Waldinger MD, Hengeveld MW, Zwinderman AH. (1994). "Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study". The American Journal of Psychiatry. 151 (9): 1377–1379. PMID 8067497.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Foster CA, Bafaloukos J. (1994). "Paroxetine in the treatment of chronic daily headache". Headache. 34 (10): 587–589. PMID 7843954.
  7. ^ Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF (2002). "A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers". Journal of Clinical Psychiatry. 63 (6): 508–512. PMID 12088162.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M (1999). "The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms". Pain. 42 (2): 135–144. PMID 2147235.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R (2002). "A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling". Journal of Clinical Psychiatry. 63 (6): 501–507. PMID 12088161.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Weitzner MA, Moncello J, Jacobsen PB, Minton S. (2002). "A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer". Journal of Pain and Symptom Management. 23 (4): 337–345. PMID 11997203.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. (2002). "Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression". Journal of Clinical Psychiatry. 63 (7): 577–584. PMID 12143913.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ FDA Warning on Birth defects
  13. ^ Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32. PMID 16430968.
  14. ^ American Society of Consultant Pharmacists - Clinical reviews
  15. ^ Haddad P (2001). "Antidepressant discontinuation syndromes". Drug Saf. 24 (3): 183–97. PMID 11347722.
  16. ^ Quitpaxil.org - Information for persons suffering from Paxil withdrawal syndrome
  17. ^ Yerevanian B, Koek R, Feusner J, Hwang S, Mintz J (2004). "Antidepressants and suicidal behaviour in unipolar depression". Acta Psychiatr Scand. 110 (6): 452–8. PMID 15521830.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ^ http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17138801&query_hl=2&itool=pubmed_docsum PMID =
  19. ^ http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16166193&query_hl=6&itool=pubmed_docsum
  20. ^ Paxil® Pediatric Settlement Web site
  21. ^ Controversial statistics, seroxatsecrets.wordpress.com, USA
  22. ^ Controversial statistics, ahrp.blogspot.com, UK
  23. ^ psychiatry online
  24. ^ paxil protest
  25. ^ National Paxil Protest invites antidepressant drugs victims to join public outcry against GlaxoSmithKline September 06, 2005
  26. ^ [ http://www.breggin.com/courtfiling.pbreggin.2006.html A press releasy by Dr. Peter Breggin]
  27. ^ seroxat secrets website
  28. ^ Hugh James Sollicitors seroxat news
  29. ^ [1]
  30. ^ [2]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Paroxetine&oldid=108187746"